Understanding the ADAPT-SC Results of Subcutaneous Efgartigimod: Tuan Vu, MD
November 2nd 2023The division director of Neuromuscular Medicine & EMG at USF Health provided an overview of the open-label findings from ADAPT-SC, a phase 3 study assessing subcutaneous efgartigimod in patients with myasthenia gravis. [WATCH TIME: 3 minutes]